Rocket Pharmaceuticals, INC 8-K filings

Rocket Pharmaceuticals successfully closed a public offering, raising approximately $178.1 million to support its pipeline development and commercialization efforts.

Rocket Pharmaceuticals' General Manager, Commercial Affairs, Mark White, has resigned effective January 1, 2025.

Rocket Pharmaceuticals reported positive long-term safety and efficacy results from its Phase 1 study of RP-A501 for Danon Disease, showing sustained improvements in cardiac function and protein expression, while also providing an update on its Pyruvate Kinase Deficiency program.

Rocket Pharmaceuticals reported its third quarter 2024 financial results, highlighted by the completion of enrollment in a pivotal Phase 2 study and progress across its gene therapy pipeline.

Rocket Pharmaceuticals has appointed Dr. Mikael Dolsten, a seasoned pharmaceutical executive, to its Board of Directors, effective September 9, 2024.

Rocket Pharmaceuticals announced its second quarter 2024 financial results, highlighting progress in its clinical programs and regulatory submissions, with a cash runway extending into 2026.

The FDA issued a Complete Response Letter to Rocket Pharmaceuticals for its KRESLADI gene therapy, requesting additional manufacturing information.

Rocket Pharmaceuticals' stockholders approved an increase in authorized common stock shares from 120 million to 180 million at the 2024 Annual Meeting, among other proposals.

Rocket Pharmaceuticals announced its first quarter 2024 financial results, highlighted by advancements in its gene therapy programs and a strengthened leadership team.

Rocket Pharmaceuticals has appointed Aaron Ondrey as Chief Financial Officer and made additional key appointments within its corporate leadership team to support its transition to a commercial-stage company.

Rocket Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting progress across its gene therapy pipeline and commercialization plans.

The FDA has extended the review period for Rocket Pharmaceuticals' KRESLADI gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I) by three months, with a new PDUFA date of June 30, 2024.